ZyVersa Therapeutics, Inc. financial data

Symbol
ZVSA on Nasdaq
Industry
Pharmaceutical Preparations
Location
217 W. Main Street, Somerville, NJ
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Larkspur Health Acquisition Corp. (to 12/9/2022)
Latest financial report
10-Q - Q2 2024 - Aug 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 21.5 % -42.4%
Debt-to-equity 89.8 % +258%
Return On Equity -173 % -10.8%
Return On Assets -90.9 % +5.38%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.03M shares
Common Stock, Shares, Outstanding 835K shares -96.5%
Entity Public Float 5.6M USD -92.7%
Common Stock, Value, Issued 83 USD -96.5%
Weighted Average Number of Shares Outstanding, Basic 835K shares +1537%
Weighted Average Number of Shares Outstanding, Diluted 835K shares +1537%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 2.15M USD -41.9%
General and Administrative Expense 8.11M USD -48%
Operating Income (Loss) -22.4M USD +75.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -22.4M USD +96.8%
Income Tax Expense (Benefit) 9.71K USD
Net Income (Loss) Attributable to Parent -21.8M USD +73.6%
Earnings Per Share, Basic 1.71K USD/shares +99.8%
Earnings Per Share, Diluted 1.71K USD/shares +99.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 214K USD
Assets, Current 641K USD -42.5%
Property, Plant and Equipment, Net 1.73K USD -85.7%
Operating Lease, Right-of-Use Asset 7.84K USD -92%
Intangible Assets, Net (Excluding Goodwill) 30.8M USD
Goodwill 11.9M USD
Other Assets, Noncurrent 18.6M USD -39.5%
Assets 19.5M USD -39.1%
Accounts Payable, Current 8.32M USD +2.12%
Accrued Liabilities, Current 1.68M USD -26.4%
Liabilities, Current 9.99M USD -4.67%
Deferred Income Tax Liabilities, Net 855K USD -40.7%
Liabilities 10.8M USD -9.03%
Retained Earnings (Accumulated Deficit) -109M USD -25.1%
Stockholders' Equity Attributable to Parent 8.62M USD -57%
Liabilities and Equity 19.5M USD -39.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.78M USD +17.7%
Net Cash Provided by (Used in) Financing Activities 2.67M USD
Net Cash Provided by (Used in) Investing Activities -2.7M USD
Common Stock, Shares Authorized 250M shares +127%
Common Stock, Shares, Issued 835K shares -96.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.1M USD +76.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 119K USD -47.8%
Deferred Tax Assets, Valuation Allowance 14.1M USD -5.12%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure
Deferred Tax Assets, Gross 17.9M USD +24.5%
Depreciation 2.6K USD 0%
Lessee, Operating Lease, Liability, to be Paid 8.66K USD -92%
Property, Plant and Equipment, Gross 52K USD 0%
Operating Lease, Liability, Current 8.66K USD -92%
Lessee, Operating Lease, Liability, to be Paid, Year One 8.7K USD -92.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 48 USD -98.8%
Deferred Tax Assets, Operating Loss Carryforwards 9.97M USD +49.5%
Deferred Federal Income Tax Expense (Benefit) -152K USD
Preferred Stock, Shares Authorized 1M shares 0%
Operating Lease, Payments 8.66K USD -64.3%
Additional Paid in Capital 117M USD +9.71%
Deferred Tax Assets, Net of Valuation Allowance 3.79M USD -73.6%
Share-based Payment Arrangement, Expense 924K USD -23.2%
Deferred State and Local Income Tax Expense (Benefit) -34.8K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%